当PD-1单抗的年销售额突破百亿美元时，全球医药界正把目光投向更艰难的战场——实体瘤细胞治疗。2024年ASCO会议数据显示，全球在研CAR-T项目中针对实体瘤的仅占12.7%，而其中进入临床II期的不足3%。在这个背景下，易慕峰IMC001新增适应症获批的消息犹如一剂强心针：这款靶向EpCAM的CAR-T产品不仅完成中美双报，更将适应症从消化系统肿瘤拓展至泛上皮源性实体瘤，其90%的疾病控制率和 ...

BioAtla is extending its runway beyond key clinical readouts in 1H 2026 by restructuring and realigning resources, which ...

本文全面阐述了 EpCAM 在 HCC 中的生物学特性、调控机制、临床意义及治疗策略。 肝细胞癌（HCC）现状与 EpCAM 研究意义 肝细胞癌是全球癌症相关死亡的主要原因之一。尽管目前有多种治疗手段，如肝切除、肝移植、化疗栓塞和全身治疗等，但手术治疗因高复发率 ...

Q4 2024 Earnings Conference Call March 27, 2025 4:30 PM ETCompany ParticipantsBruce Mackle - LifeSci Advisors, ...

BioAtla is laying off 30% of staff as the biotech searches for partners for some of its conditionally active biologic (CAB) ...

New milestone achieved in Astellas T-cell engager collaboration: In February 2025, Astellas advanced the second program to GLP toxicology studies, triggering a $5 million milestone payment to CytomX.

Reports cash and cash equivalents as of December 31, were $49M , compared to $111.5M as of December 31, 2023. We expect that cost reductions ...

Good afternoon, everyone. Thank you for standing by. Welcome to CytomX Therapeutics Fourth Quarter 2024 Financial Results Call. Please be advised that, today's call is being recorded. I would now ...

Revenue: $138.1 million for the full year 2024, up from $101.2 million in 2023. Total Operating Expenses: $113.1 million for 2024, compared to $107.7 million in 2023. R&D Expenses: Increased by $5 ...

BioAtla is a global clinical-stage biotechnology company with operations in San Diego, California, and in Beijing, China ...